Molecular imaging and carbonic anhydrase IX-targeted radioimmunotherapy in clear cell renal cell carcinoma

Positron Emission Tomography/Computed Tomography Identification of Clear Cell Renal Cell Carcinoma: Results From the REDECT Trial

(2012) Chaitanya R. Divgi et al.   JOURNAL OF CLINICAL ONCOLOGY

Bone Marrow Dosimetry Using 124I-PET

(2012) J. Schwartz et al.   JOURNAL OF NUCLEAR MEDICINE

Multimodal Imaging and Detection Strategy With 124 I-Labeled Chimeric Monoclonal Antibody cG250 for Accurate Localization and Confirmation of Extent of Disease During Laparoscopic and Open Surgical Resection of Clear Cell Renal Cell Carcinoma

(2012) Stephen P. Povoski et al.   Surgical Innovation

Meta-analysis of the diagnostic performance of [18F]FDG-PET and PET/CT in renal cell carcinoma

(2012) Hsin-Yi Wang et al.   CANCER IMAGING

Proposal for the standardisation of multi-centre trials in nuclear medicine imaging: prerequisites for a European 123I-FP-CIT SPECT database

(2011) John Caddell Dickson et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Dosimetric Analysis of 177Lu-cG250 Radioimmunotherapy in Renal Cell Carcinoma Patients: Correlation with Myelotoxicity and Pretherapeutic Absorbed Dose Predictions Based on 111In-cG250 Imaging

(2011) A. B. Stillebroer et al.   JOURNAL OF NUCLEAR MEDICINE

Correlation of In Vivo and In Vitro Measures of Carbonic Anhydrase IX Antigen Expression in Renal Masses Using Antibody 124I-cG250

(2011) D. A. Pryma et al.   JOURNAL OF NUCLEAR MEDICINE

Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial

(2011) Brian I Rini et al.   LANCET

Carbonic Anhydrase IX Expression in Renal Neoplasms

(2010) Elizabeth M. Genega et al.   AMERICAN JOURNAL OF CLINICAL PATHOLOGY

Phase 3 trial of everolimus for metastatic renal cell carcinoma

(2010) Robert J. Motzer et al.   CANCER

Phase III Trial of Bevacizumab Plus Interferon Alfa-2a in Patients With Metastatic Renal Cell Carcinoma (AVOREN): Final Analysis of Overall Survival

(2010) Bernard Escudier et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase III Trial of Bevacizumab Plus Interferon Alfa Versus Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: Final Results of CALGB 90206

(2010) Brian I. Rini et al.   JOURNAL OF CLINICAL ONCOLOGY

Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial

(2010) Cora N. Sternberg et al.   JOURNAL OF CLINICAL ONCOLOGY

Interferon alfa-2a versus combination therapy with interferon alfa-2a, interleukin-2, and fluorouracil in patients with untreated metastatic renal cell carcinoma (MRC RE04/EORTC GU 30012): an open-label randomised trial

(2010) Martin E Gore et al.   LANCET

Epidemiology and risk factors for kidney cancer

(2010) Wong-Ho Chow et al.   Nature Reviews Urology

The reverse side of the victory: Flare up of symptoms after discontinuation of sunitinib or sorafenib in renal cell cancer patients. A report of three cases

(2009) Ingrid M. E. Desar et al.   ACTA ONCOLOGICA

Tyrosine Kinase Inhibitors – A Review on Pharmacology, Metabolism and Side Effects

(2009) Jorg Hartmann et al.   CURRENT DRUG METABOLISM

11C-Acetate PET imaging for renal cell carcinoma

(2008) Nobuyuki Oyama et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Low CAIX expression and absence of VHL gene mutation are associated with tumor aggressiveness and poor survival of clear cell renal cell carcinoma

(2008) Jean-Jacques Patard et al.   INTERNATIONAL JOURNAL OF CANCER

Contemporary Results of Percutaneous Biopsy of 100 Small Renal Masses: A Single Center Experience

(2008) Alessandro Volpe et al.   JOURNAL OF UROLOGY

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

(2008) Robert J Motzer et al.   LANCET

Diagnostic Accuracy of Computed Tomography-Guided Percutaneous Biopsy of Renal Masses

(2007) Joerg Schmidbauer et al.   EUROPEAN UROLOGY